Most attempts to limit tropism have used chimeric envelope proteins bearing antibody fragments.

This observation has led to the development of a new type of antibody fragments with potential use as drugs, so-called single-domain antibodies.

Various antivenom treatments exist, typically consisting of antibodies or antibody fragments, which neutralize the venom.

This means that, although antibody fragments created using display methods are of fully human sequence, they are not full antibodies.

A secondary antibody is an antibody that binds to primary antibodies or antibody fragments.

Fab and F(ab')2 antibody fragments are used in assay systems where the presence of the Fc region may cause problems.

We have made retrovirus particles displaying a functional antibody fragment.

This suggested that the functional antibody fragment could be incorporated into virion particles and displayed at their surface.

Antidigoxin antibody fragments, the specific treatment for digoxin poisoning, are also effective in serious digitoxin toxicity.

One possible solution is the use of antibody fragments containing just enough of the constant region to hold the molecule together.